Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

CD70-targeted immunoPET Imaging of Malignant Cancers

A Study of the Clinical Application of CD70-targeted PET/ CT Imaging in the Diagnosis of Malignant Cancers

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to establish and optimize the cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological distribution characteristics, based on which the diagnostic efficacy of the above imaging agents in malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) will be evaluated.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged 18-80 year-old and of either sex； - diagnosed by tissue sample (biopsy-confirmed) diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; - Capable of giving signed willing to sign a consent form, including compliance with the requirements and restrictions in the willing to sign a consent form form (ICF) and this protocol. Who Should NOT Join This Trial: - Pregnancy； - Severe hepatic and renal insufficiency; - Allergic to single-domain antibody radiopharmaceuticals. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Aged 18-80 year-old and of either sex； * Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; * Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol. Exclusion Criteria: * Pregnancy； * Severe hepatic and renal insufficiency; * Allergic to single-domain antibody radiopharmaceuticals.

Treatments Being Tested

DRUG

[18F]F-RESCA-RCCB6

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.

DRUG

[18F]F-RESCA-R8B4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.

DRUG

[18F]F-RESCA-RD06

Enrolled patients will receive 0.05-0.1 mCi/kg of \[18F\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RD06 injection.

DRUG

[68Ga]Ga-NOTA-R8B4

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.

DRUG

[68Ga]Ga-NOTA-RD06

Enrolled patients will receive 0.05-0.1 mCi/kg of \[68Ga\]RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]RD06 injection.

DRUG

[89Zr]Zr-DFO-RB6

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RB6 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

DRUG

[89Zr]Zr-DFO-R8B4

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-R8B4 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

DRUG

[89Zr]Zr-DFO-RD06

Enrolled patients will receive a single dose (1-3 mCi) of \[89Zr\]Zr-DFO-RD06 (total 1-2 mg antibody mass). Multiple immunoPET/CT imaging sessions will be performed on day 0, day 1(24 h), day 3 (72 h), day 5 (120 h) or day 7 (168 h).

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Shanghai, China